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Omeprazole inhibits the gastric secretion by altering the activity of H + /K+ ATPase1,2. The drug itself
is inactive but is converted to the active form, a sulfonamide in the acid milieu of canaliculi of actively
secreting gastric parietal cells3. Though the plasma half life is 60 minutes, the drug binds covalently
with H+/K+ATPase and duration of action is thereafter increased to greater than 24 hours4. Distal
oesophagitis is a complication of gastro-oesophageal reflux. Number and duration of episodes of reflux
are important in the pahogenesis5-7. The aim of this study was to assess the efficacy of omeprazole 20
mg once daily in our patients for short term treatment of refiux oesophagitis.
PATIENTS, METHODS AND RESULTS
This was an open labeled, non-comparative single centre study. Outpatients aged 18-70 with
endoscopic findings of reflux oesophagitis (grade I to III) were included in the study. Exclusion criteria
were pregnant and lactating mothers, treatment with anti-ulcer or anti-refiux drugs within a week prior
to inclusion, patients with concomitant gastric or duodenal ulcer, pyloric stenosis, or any malignant
lesion as evident on gastroscopy, oesophageal varices, stricture or Barrett’s oesophagus, previous
gastro-oesophageal surgery, patients with abnormal renal or hepatic functions and patients requiring
regular use of NSAIDs. Before entry, the severity of symptoms and personal habits were assessed. A
complete physical examination was performed. Lab investigations including complete blood count
(CBC), ESR, urinalysis, blood urea nitrogen (BUN), creatinine, biirubin, alanine aminotransferase
(ALT) and alkaline phosphatase were done. Endoscopy was performed within a week prior to the
inclusion. Informed consent was taken from all the patients. Patients’ symptoms like heart burns and
pains were graded from 0 (none) to 3 (severe). Occasional episodes not interfering with the normal
activity corresponded to grade 1 (mild), episodes interfering with normal activity as grade 2
(moderate), frequent episodes constantly interfering with normal activity as grade 3 (severe).
Oesophagitis was graded as follows: Grade I, erythema, hyperemia or mucosal friability; grade II,
superficial erosions; grade III, ulcerations and grade W, complications, e.g., strictures. Patients were
seen at two and four weeks to record severity of symptoms and any adverse effects, physical
examination and check of left over capsules. Concomitant use of anti-refiux or other anti-ulcer drugs
was forbidden during the study period. Endoscopy was repeated by the same endoscopist at 29±3 days
and laboratory tests performed. Thirty consecutive patients were entered in the study. The clinical
characteristics and results are summarized in

Table I and II and Figure 1 and 2.

Healing defined as complete disappearance of all the lesions and re-epithelization of oesophageal
mucosa on endoscopic examination was seen in 19 of 30 patients (68%). Twenty of 30 patients became
asymptomatic and another 9 patients improved symptomatically. No major clinical or biochemical side
effects were observed. Only one patient complained of some decrease in appetite but he completed the
trial.
COMMENTS
The randomized clinical trials have proved the superiority of omeprazole over H2 - receptor
antagonists8-13. The healing rate at 4 weeks varied between 67-85% as compared to 27-31% when
using ranitidine. Much higher healing rate was observed at 8 weeks with omeprazole; 85-96% with
omeprazole vs 38-50% with ranitidine11-13. There was significantly better symptomatic improvement
with omeprazole. Our results are in accordance with the previous studies. We used 20 mg of
omeprazole daily and assessed our patients at 4 weeks. The healing rate was 63%. Complete healing
was observed in all the cases of grade I oesophagitis and in majority of the patients of grade 11(10 out
of 17). The studies indicate that the acid is the major factor in the development of reflux oesophagitis.
Omeprazole 20 mg produces 90% reduction in the intragastric acidity whereas 40-60 mg produces 9698% reduction14-16. Elevation of gastric pH heals peptic oesophagitis but it does not significantly effect
the frequency of postprandial transient lower oesophageal sphincter relaxations and magnitude of basal
lower oesophageal sphincter pressure17,18. Also omeprazole has no significant effect on gastric
emptying in humans19.
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